Ocular Therapeutix (OCUL) Cash from Investing Activities (2013 - 2026)

Ocular Therapeutix's Cash from Investing Activities history runs 14 years deep, the most recent figure standing at -$4.7 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 141.18% year-over-year to -$4.7 million; the TTM figure through Mar 2026 stood at -$14.6 million (down 392.55% YoY), while the FY2025 annual figure was -$11.9 million, down 822.36% from the prior year.
• Cash from Investing Activities was -$4.7 million for Q1 2026 at Ocular Therapeutix, down from -$2.8 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of -$89000.0 in Q3 2024 to a low of -$6.0 million in Q3 2025.
• Historically, Cash from Investing Activities has averaged -$1.6 million across 5 years, with a median of -$794000.0 in 2022.
• The sharpest annual moves came in 2024 and 2025: Cash from Investing Activities surged 92.45% in 2024, then sank 6633.71% in 2025.
• A 5-year view of Cash from Investing Activities shows it stood at -$2.2 million in 2022, then jumped by 78.65% to -$459000.0 in 2023, then surged by 55.99% to -$202000.0 in 2024, then sank by 1305.45% to -$2.8 million in 2025, then tumbled by 64.21% to -$4.7 million in 2026.
• The last three Cash from Investing Activities figures came in at -$4.7 million (Q1 2026), -$2.8 million (Q4 2025), and -$6.0 million (Q3 2025), per Business Quant data.